dgat1

DGAT1-IN-1 is a potent inhibitor of diacylglycerol O-acyltransferase type 1 (DGAT1) with an IC50 of less than 10 nM.

DGAT1-IN-3 is a selective, potent, orally active DGAT-1 inhibitor that inhibits human DGAT-1 (IC50: 38 nM) and rat DGAT-1 (IC50: 120 nM).DGAT1-IN-3 can be used in studies of obesity, dyslipidemia and metabolic syndrome.

JNJ-DGAT1-A is a DGAT1-selective inhibitor.

DGAT-1 inhibitor 2 is an effective DGAT-1 inhibitor and anti-obesity drug. DGAT-1 (acyl-CoA: diacylglycerol acyltransferase 1) is one of two known DGAT enzymes that catalyze the final step of triglyceride synthesis. Transgenic mice and pharmacological studies indicate that inhibiting DGAT1 is a promising strategy for treating obesity and type 2 diabetes.

Pradigastat (LCQ-908) is an orally active, potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor for the treatment of constipation, which may be used in the study of obesity and diabetes.

PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM.

Amidinomalonamide hydrochloride is a chemical reagent used in the preparation of pyrimidooxazines used as DGAT1 inhibitors. This drug has potential use as an anti-obesity treatment.

T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. IC50 value: Target: DGAT1 T863 (DGAT-3) causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.

Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether, an inhibitor of DGAT1, exhibits an IC50 of 92.7 μM and is extracted from Eleutherococcus senticosus. This compound is utilized in research related to Type II diabetes and obesity.

GSK2973980A is a selective Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitor (IC50: 3 nM).

Diacylglycerol Acyltransferase Inhibitor-1, a diacylglycerol acyltransferase (DGAT1) inhibitor, effectively suppresses the activity of DGAT1.

ALN29882 is a glycerolipid, that is located at the plasma membrane. It is made up of two fatty acid chains that are covalently attached to a single glycerol molecule with the help of an ester linkage. 18:1 DG has been used as a diacyl-glycerol source in diacylglycerol O-acyltransferase 1 (DGAT1) assay. It has also been used as substrate to assess compounds as potential inhibitors of DGAT-1 in DGAT-1 enzyme assay. It is suitable to use in lipid-protein overlay screen assay with the recombinant protein His-AtROP6.

AZD3988 is an orally active and highly potent inhibitor of diacylglycerol acyltransferase-1 (DGAT-1) for the study of diabetes and obesity.

7beta-Methoxyrosmanol inhibited acyl CoA:diacylglycerol acyltransferase (DGAT)1 activity, with the IC50 values ranging from 39.5 ± 0.6 to 144.2 ± 3.1 μM.

AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). IC50 value: 80 nM [1] Target: DGAT1 in vitro: Plasma AZD7687 exposure was measured repeatedly. AZD7687 markedly reduced postprandial TAG excursion with a steep concent

AZD2353 is a potent inhibitor of diacylglycerol acetyl transferase 1 (DGAT1).